-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 7, NMPA's official website showed that Tianjin Jinyao Pharmaceutical's metahydroxylamine bitartrate injection passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
Metahydroxylamine is a commonly used classic booster drug, with terminal sales of more than 500 million yuan in Chinese public medical institutions in 2020
.
.
Metahydroxylamine is a commonly used classic booster drug, with terminal sales of more than 500 million yuan in Chinese public medical institutions in 2020
.
Metahydroxylamine Bitartrate Injection is a vasopressor drug used to treat various shocks and hypotension during surgery
.
As a first aid drug , metahydroxylamine bitartrate injection has been included in the list of shortage drugs for many times
.
.
As a first aid drug , metahydroxylamine bitartrate injection has been included in the list of shortage drugs for many times
.
In recent years, the domestic market of metahydroxyamine has maintained a rapid growth trend
.
According to data from Minet.
com, in 2020, the sales of terminal metahydroxylamine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 500 million yuan, a year-on-year increase of 41.
57%; The sales exceeded 300 million yuan, a year-on-year increase of 70.
68%
.
.
According to data from Minet.
com, in 2020, the sales of terminal metahydroxylamine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 500 million yuan, a year-on-year increase of 41.
57%; The sales exceeded 300 million yuan, a year-on-year increase of 70.
68%
.
Sales of terminal metahydroxylamine in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Although there are 11 domestic companies that have the production approval for m-hydroxyamine bitartrate injection, there are not many companies that sell them on the market
.
Among the 11 companies, only Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical submitted supplementary applications for the consistency evaluation of metahydroxyamine bitartrate injection
.
.
Among the 11 companies, only Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical submitted supplementary applications for the consistency evaluation of metahydroxyamine bitartrate injection
.
Tianjin Jinyao Pharmaceutical Co.
, Ltd.
took the lead in passing the consistency evaluation and became the first domestic company to pass the evaluation, which is conducive to expanding the market share of this product and enhancing market competitiveness
.
, Ltd.
took the lead in passing the consistency evaluation and became the first domestic company to pass the evaluation, which is conducive to expanding the market share of this product and enhancing market competitiveness
.
On March 7, NMPA's official website showed that Tianjin Jinyao Pharmaceutical's metahydroxylamine bitartrate injection passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
Metahydroxylamine is a commonly used classic booster drug, with terminal sales of more than 500 million yuan in Chinese public medical institutions in 2020
.
.
Metahydroxylamine is a commonly used classic booster drug, with terminal sales of more than 500 million yuan in Chinese public medical institutions in 2020
.
Metahydroxylamine Bitartrate Injection is a vasopressor drug used to treat various shocks and hypotension during surgery
.
As a first aid drug , metahydroxylamine bitartrate injection has been included in the list of shortage drugs for many times
.
.
As a first aid drug , metahydroxylamine bitartrate injection has been included in the list of shortage drugs for many times
.
In recent years, the domestic market of metahydroxyamine has maintained a rapid growth trend
.
According to data from Minet.
com, in 2020, the sales of terminal metahydroxylamine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 500 million yuan, a year-on-year increase of 41.
57%; The sales exceeded 300 million yuan, a year-on-year increase of 70.
68%
.
.
According to data from Minet.
com, in 2020, the sales of terminal metahydroxylamine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 500 million yuan, a year-on-year increase of 41.
57%; The sales exceeded 300 million yuan, a year-on-year increase of 70.
68%
.
Sales of terminal metahydroxylamine in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Although there are 11 domestic companies that have the production approval for m-hydroxyamine bitartrate injection, there are not many companies that sell them on the market
.
Among the 11 companies, only Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical submitted supplementary applications for the consistency evaluation of metahydroxyamine bitartrate injection
.
.
Among the 11 companies, only Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical submitted supplementary applications for the consistency evaluation of metahydroxyamine bitartrate injection
.
Tianjin Jinyao Pharmaceutical Co.
, Ltd.
took the lead in passing the consistency evaluation and became the first domestic company to pass the evaluation, which is conducive to expanding the market share of this product and enhancing market competitiveness
.
, Ltd.
took the lead in passing the consistency evaluation and became the first domestic company to pass the evaluation, which is conducive to expanding the market share of this product and enhancing market competitiveness
.
On March 7, NMPA's official website showed that Tianjin Jinyao Pharmaceutical's metahydroxylamine bitartrate injection passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
Metahydroxylamine is a commonly used classic booster drug, with terminal sales of more than 500 million yuan in Chinese public medical institutions in 2020
.
.
Metahydroxylamine is a commonly used classic booster drug, with terminal sales of more than 500 million yuan in Chinese public medical institutions in 2020
.
Metahydroxylamine Bitartrate Injection is a vasopressor drug used to treat various shocks and hypotension during surgery
.
As a first aid drug , metahydroxylamine bitartrate injection has been included in the list of shortage drugs for many times
.
medicines medicines medicines.
As a first aid drug , metahydroxylamine bitartrate injection has been included in the list of shortage drugs for many times
.
In recent years, the domestic market of metahydroxyamine has maintained a rapid growth trend
.
According to data from Minet.
com, in 2020, the sales of terminal metahydroxylamine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 500 million yuan, a year-on-year increase of 41.
57%; The sales exceeded 300 million yuan, a year-on-year increase of 70.
68%
.
hospital hospital hospital.
According to data from Minet.
com, in 2020, the sales of terminal metahydroxylamine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 500 million yuan, a year-on-year increase of 41.
57%; The sales exceeded 300 million yuan, a year-on-year increase of 70.
68%
.
Sales of terminal metahydroxylamine in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Although there are 11 domestic companies that have the production approval for m-hydroxyamine bitartrate injection, there are not many companies that sell them on the market
.
Among the 11 companies, only Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical submitted supplementary applications for the consistency evaluation of metahydroxyamine bitartrate injection
.
enterprise enterprise enterprise.
Among the 11 companies, only Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical submitted supplementary applications for the consistency evaluation of metahydroxyamine bitartrate injection
.
Tianjin Jinyao Pharmaceutical Co.
, Ltd.
took the lead in passing the consistency evaluation and became the first domestic company to pass the evaluation, which is conducive to expanding the market share of this product and enhancing market competitiveness
.
, Ltd.
took the lead in passing the consistency evaluation and became the first domestic company to pass the evaluation, which is conducive to expanding the market share of this product and enhancing market competitiveness
.
